Regulatory Approval

Showing 898 articles
Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

Columbia Financial to Acquire Northfield Bancorp in $597 Million Deal, Sets 2026 Timeline for Full Public Conversion

Columbia Financial (NASDAQ: CLBK) has announced a definitive agreement to merge with Northfield Bancorp in an all-stock transaction valued at approximately $597 million. The deal, slated to close in early Q3 2026, coincides with Columbia's planned "second-step" conversion to a fully public company, a move executives say will unlock value and create a leading regional bank in the New Jersey-New York metro area.